Table 2 Baseline characteristics and follow-up of each patient
Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | |
|---|---|---|---|---|---|---|
Sex | male | male | male | male | male | male |
Age (years) | 58 | 64 | 80 | 69 | 59 | 76 |
Hypertension | yes | yes | yes | yes | yes | yes |
Diabetes | yes | yes | no | yes | no | no |
Hyperlipidemia | no | no | no | no | no | no |
CAD | no | yes | no | yes | no | no |
Prior MI | no | yes | no | no | no | no |
Smoking | no | yes | yes | yes | yes | yes |
Previous medications | ||||||
Beta-blocker | no | yes | no | yes | no | no |
ACEI or ARB | yes | no | yes | yes | no | no |
CCB | yes | yes | yes | yes | yes | yes |
Statin | no | no | no | no | no | no |
Cancer type | lung | lung | liver | lung | esophagus | lung |
ICI type | P | P | P | T | T | T |
1st ICI to pacing | 23 days | 30 days | 51 days | 34 days | 24 days | 24 days |
Dyspnea | no | yes | yes | yes | yes | yes |
Chest pain or tightness | no | yes | yes | yes | no | no |
Myasthenia | no | no | no | no | yes | no |
Myalgia | no | no | no | no | yes | no |
Blepharoptosis | no | no | no | yes | yes | yes |
Diplopia | yes | no | no | no | yes | no |
Syncope | yes | no | no | no | yes | yes |
VT | no | no | yes | yes | no | no |
HF | no | yes | yes | yes | no | yes |
Cardiac Shock | no | yes | no | yes | no | yes |
AVB | Comp. | Comp. | Comp. | Comp. | Comp. | Adv. |
LVEF (%) | 73 | 56 | 67 | 67 | 77 | 38 |
cTnI (µg/L) | 7.7 | 15.3 | 0.6 | 11.7 | 2.0 | 20.3 |
CK (U/L) | 3130.0 | 4673.0 | 2023.0 | 285.0 | 1058.0 | 13876.0 |
CKMB (µg/L) | 53.1 | 128.1 | 36.4 | 43.9 | 23.6 | 369.0 |
NT-proBNP (pg/ml) | 503.0 | 1236.0 | 3720.0 | 859.0 | 171.0 | 3628.0 |
SCr, µmol/L | 73.0 | 80.0 | 47.0 | 65.0 | 59.0 | 74.0 |
hsCRP, mg/L | 24.5 | 13.0 | 9.2 | 0.5 | 1.36 | 31.40 |
Myositis | no | yes | no | yes | yes | yes |
Hepatitis | no | yes | no | yes | no | no |
Treatments | ||||||
Intravenous isoproterenol | no | no | yes | yes | no | yes |
MP | yes | yes | yes | yes | yes | yes |
MP pulse | yes | yes | no | no | yes | yes |
IVIG | no | yes | yes | yes | yes | yes |
Tocilizumab | no | no | no | yes | yes | yes |
ACEI or ARB | yes | no | yes | yes | yes | no |
CCB | yes | yes | yes | yes | no | no |
Invasive ventilation | no | yes | no | no | no | yes |
Vasoactive drugs | no | yes | no | yes | no | yes |
TPM lead | passive | passive | passive | passive | passive | passive |
Vein access | femoral | femoral | femoral | femoral | femoral | femoral |
RV pacing site | septum | septum | septum | septum | apex | apex |
RV T(V@0.4ms) | 1.0 | 1.0 | 1.0 | 1.4 | 1.0 | 2.2 |
RV S(mV) | NA | NA | NA | NA | NA | NA |
RV I(Ω) | NA | NA | NA | NA | NA | NA |
Follow-up(days) | 377 | 147 | 1119 | 8 | 228 | 14 |
AVC recover | no | yes | no | no | no | no |
PPM | yes | no | yes | no | yes | no |
Primary endpoint | survival | survival | survival | dead | survival | dead |